Over recent years, P4HA2 has been aberrantly overexpressed in various tumors, accelerating their malignant progression, including in B-cell lymphoma, breast cancer, and prostate cancer10–12. Here, P4HA2 is linked to B-cell non-Hodgkin lymphoma.